ClinicalTrials.gg
CompletedNCT03250377Updated Jul 29, 2025Results posted

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

A Phase 3 interventional study of Brivaracetam in Partial Seizures With or Without Secondary Generalization and Epilepsy, sponsored by UCB Biopharma SRL. Completed at 59 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
11th of 34
207 · median 94
Started
2017
with 2 others
Phase 3
21 of 34
1 open now
Registered
23rd of 34
by date
Lead sponsor
7 of 34
UCB Biopharma SRL

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 11th largest by enrollment, is one of 3 that started in 2017, is one of 21 in phase 3, and was the 23rd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.

03

Conditions studied

  • Partial Seizures With or Without Secondary Generalization
  • Epilepsy

Browse trials for

Keywords

  • Brivaracetam
  • Epilepsy
  • Partial seizures with or without secondary generalization
  • Briviact
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/female study participant from 16 years of age or older. Study participant who are not legal adults may only be included where legally permitted and ethically accepted
  • Study participant completed the Treatment Period and Transition Period of EP0083 or is ongoing in N01379 sites in Japan
  • Female study participants with are eligible if they use a medically accepted method
  • Inclusion Criteria for directly enrollers only: Study participant has 1 to \<8 partial seizures (according to the 1981 International League Against Epilepsy (ILAE) classification) during the 8 weeks prior to brivaracetam (BRV) administration

Exclusion criteria

Exclusion Criteria:

  • Study participant has developed to any components of the medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the core study
  • Severe medical, neurological or psychiatric disorders, or laboratory values which may have an impact on the safety of the study participant
  • Poor compliance with the visit schedule or medication intake in the previous BRV studies
  • Planned participation in any other clinical study of another investigational drug or device during this study
  • Pregnant or lactating woman
  • Any medical condition which, in the Investigator's opinion, warrants exclusion
  • Study participant has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months
  • Study participant has >2 x (ULN) of any of the following at the Entry Visit (EV): (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total (≥1.5x ULN total bilirubin if known Gilbert's syndrome)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Subjects randomized to this arm will receive open-label Brivaracetam

    Drug: Brivaracetam

Interventions

  • * Pharmaceutical form: Film-coated tablet * Concentration: 25 mg and 50 mg * Route of administration: Oral use

    Also known as: Briviact

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as AEs that had onset on or after the day of first BRV dose in EP0085 study.

    Time frame: From Baseline until end of the safety follow up (up to 88.5 months)

Secondary outcomes

  1. Percent Change in Partial Seizure Frequency (PSF) Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants

    The seizure frequency was calculated as number of seizures per 28 days. Percent change of 28 day PSF from Baseline was defined as the percentage reduction of 28 day PSF for a designated post-baseline period in EP0085 compared with the Baseline 28 day PSF in the core study. Change in seizure frequency from Baseline was calculated: percent change = (\[Baseline 28 day PSF - Post Baseline 28 day PSF\]/\[Baseline 28 day PSF\]) × 100. For rollovers, the Baseline period was obtained from the core studies of EP0083 and N01358 directly. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

    Time frame: Baseline of EP0083 or N01358 and up to 84 months of Evaluation Period

  2. 50 Percent (%) Responder Rate in Partial Seizure Frequency Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants

    The seizure frequency was calculated as number of seizures per 28 days. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the baseline period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

    Time frame: Baseline of EP0083 or N01358 and up to 84 months of Evaluation Period

  3. Percent Change in Partial Seizure Frequency Per 28 Days From Baseline of Directly Enrolled Study Participants to the Evaluation Period

    The seizure frequency was calculated as number of seizures per 28 days. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Change in seizure frequency is calculated as the seizure frequency at the evaluation time point minus the seizure frequency at Baseline of directly enrolled participants. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

    Time frame: Baseline (8 weeks prior to BRV administration), up to 39 months of Evaluation Period

  4. 50 % Responder Rate in Partial Seizure Frequency Per 28 Days Over the Evaluation Period for Directly Enrolled Study Participants

    The seizure frequency for directly enrolled participants was calculated as number of seizures per 28 days from 8 weeks prior to BRV administration. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the Baseline Period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

    Time frame: Baseline (8 weeks prior to BRV administration), up to 39 months of Evaluation Period

  5. Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Rollover Study Participants

    A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

    Time frame: During the Evaluation Period (up to 84 months)

  6. Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Rollover Study Participants

    A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

    Time frame: During the Evaluation Period (up to 84 months)

  7. Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Rollover Study Participants

    A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

    Time frame: During the Evaluation Period (up to 84 months)

  8. Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Directly Enrolled Study Participants

    A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

    Time frame: During the Evaluation Period (up to 39 months)

  9. Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Directly Enrolled Study Participants

    A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

    Time frame: During the Evaluation Period (up to 39 months)

  10. Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Directly Enrolled Study Participants

    A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

    Time frame: During the Evaluation Period (up to 39 months)

07

Results

Posted Jul 29, 2025

Participant flow

The study started to enroll participants in August 2017 and concluded in December 2024.

Participant flow — Overall Study
MilestoneEP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRV
Started54112734
Evaluation period54112734
Down-titration period2032515
Study drug-free period3976517
Completed3774420
Not completed1738314
Withdrew: Adverse event2404
Withdrew: Lack of efficacy51413
Withdrew: Protocol violation0201
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject7704
Withdrew: Investigator's judgment1000
Withdrew: She wanted to change other therapeutic medication1000
Withdrew: The subject go abroad and not return1000
Withdrew: Epilepsy surgery0120
Withdrew: Subject moved to kanagawa (faraway from clinic)0100
Withdrew: Request from the sponsor0100
Withdrew: Subject did not follow procedure or study drug0100
Withdrew: Subject stopped drug; did not wish to continue0100
Withdrew: Subjects did not follow procedures or medication0100
Withdrew: Pregnancy event0100
Withdrew: Pi's opinion:subject noncompliant with medication0100
Withdrew: Subjects felt no effect;want to discontinue study0100
Withdrew: Subjects underweight; intolerant to study drugs0100
Withdrew: Patient requested to change hospital0001
Withdrew: Admission to geriatric health facility0001

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as AEs that had onset on or after the day of first BRV dose in EP0085 study.

Time frame:
From Baseline until end of the safety follow up (up to 88.5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsEP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRV
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)88.995.510094.1
SecondaryPercent Change in Partial Seizure Frequency (PSF) Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants

The seizure frequency was calculated as number of seizures per 28 days. Percent change of 28 day PSF from Baseline was defined as the percentage reduction of 28 day PSF for a designated post-baseline period in EP0085 compared with the Baseline 28 day PSF in the core study. Change in seizure frequency from Baseline was calculated: percent change = (\[Baseline 28 day PSF - Post Baseline 28 day PSF\]/\[Baseline 28 day PSF\]) × 100. For rollovers, the Baseline period was obtained from the core studies of EP0083 and N01358 directly. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

Time frame:
Baseline of EP0083 or N01358 and up to 84 months of Evaluation Period
Reported as:
Median · percent change
Percent Change in Partial Seizure Frequency (PSF) Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants
percent changeEP0083 PlaceboEP0083 BRV AllN01379 BRV
Percent Change in Partial Seizure Frequency (PSF) Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants60.6 (-87 to 100)43.2 (-497 to 100)67.0 (-72 to 100)
Secondary50 Percent (%) Responder Rate in Partial Seizure Frequency Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants

The seizure frequency was calculated as number of seizures per 28 days. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the baseline period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

Time frame:
Baseline of EP0083 or N01358 and up to 84 months of Evaluation Period
Reported as:
Number · percentage of responders
50 Percent (%) Responder Rate in Partial Seizure Frequency Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants
percentage of respondersEP0083 PlaceboEP0083 BRV AllN01379 BRV
50 Percent (%) Responder Rate in Partial Seizure Frequency Per 28 Days From Baseline of EP0083 or N01358 to the Evaluation Period for Rollover Study Participants66.747.357.1
SecondaryPercent Change in Partial Seizure Frequency Per 28 Days From Baseline of Directly Enrolled Study Participants to the Evaluation Period

The seizure frequency was calculated as number of seizures per 28 days. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Change in seizure frequency is calculated as the seizure frequency at the evaluation time point minus the seizure frequency at Baseline of directly enrolled participants. A negative value in percent change from Baseline indicates a decrease in PSF from Baseline. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

Time frame:
Baseline (8 weeks prior to BRV administration), up to 39 months of Evaluation Period
Reported as:
Median · percent change
Percent Change in Partial Seizure Frequency Per 28 Days From Baseline of Directly Enrolled Study Participants to the Evaluation Period
percent changeDirect Enrollers BRV
Percent Change in Partial Seizure Frequency Per 28 Days From Baseline of Directly Enrolled Study Participants to the Evaluation Period-32.6 (-3691 to 100)
Secondary50 % Responder Rate in Partial Seizure Frequency Per 28 Days Over the Evaluation Period for Directly Enrolled Study Participants

The seizure frequency for directly enrolled participants was calculated as number of seizures per 28 days from 8 weeks prior to BRV administration. 50% responders were defined as a participant with a \>= 50% reduction in seizure frequency from the Baseline Period over the post-baseline period. Percentages are based on the number of participants who performed the seizure assessment at each time point. For direct enrollers, the Baseline Period was defined as seizure counts collected from 8 weeks prior to the first BRV administration in EP0085. Evaluation Period values for seizure frequency were calculated from the seizure diary data collected during the Evaluation Period on/after the first BRV administration.

Time frame:
Baseline (8 weeks prior to BRV administration), up to 39 months of Evaluation Period
Reported as:
Number · percentage of responders
50 % Responder Rate in Partial Seizure Frequency Per 28 Days Over the Evaluation Period for Directly Enrolled Study Participants
percentage of respondersDirect Enrollers BRV
50 % Responder Rate in Partial Seizure Frequency Per 28 Days Over the Evaluation Period for Directly Enrolled Study Participants26.5
SecondaryPercentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Rollover Study Participants

A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

Time frame:
During the Evaluation Period (up to 84 months)
Reported as:
Number · percentage of participants
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Rollover Study Participants
percentage of participantsEP0083 PlaceboEP0083 BRV AllN01379 BRV
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Rollover Study Participants15.419.828.6
SecondaryPercentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Rollover Study Participants

A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

Time frame:
During the Evaluation Period (up to 84 months)
Reported as:
Number · percentage of participants
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Rollover Study Participants
percentage of participantsEP0083 PlaceboEP0083 BRV AllN01379 BRV
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Rollover Study Participants8.314.033.3
SecondaryPercentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Rollover Study Participants

A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

Time frame:
During the Evaluation Period (up to 84 months)
Reported as:
Number · percentage of participants
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Rollover Study Participants
percentage of participantsEP0083 PlaceboEP0083 BRV AllN01379 BRV
Participants with partial seizure-freedom1.97.114.3
Participants with all-type seizure-freedom1.97.114.3
SecondaryPercentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Directly Enrolled Study Participants

A study participant was considered seizure free, if no seizure occurred during 6 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

Time frame:
During the Evaluation Period (up to 39 months)
Reported as:
Number · percentage of participants
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Directly Enrolled Study Participants
percentage of participantsDirect Enrollers BRV
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 6 Months During the Evaluation Period for Directly Enrolled Study Participants24.1
SecondaryPercentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Directly Enrolled Study Participants

A study participant was considered seizure free, if no seizure occurred during 12 consecutive months in the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

Time frame:
During the Evaluation Period (up to 39 months)
Reported as:
Number · percentage of participants
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Directly Enrolled Study Participants
percentage of participantsDirect Enrollers BRV
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types (Partial, Generalized, and Unclassified Epileptic Seizure) for at Least 12 Months During the Evaluation Period for Directly Enrolled Study Participants15.4
SecondaryPercentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Directly Enrolled Study Participants

A study participant was considered seizure free (partial, all epileptic seizure), if no seizure occurred during the Evaluation Period and if met all of the following criteria: - the participant completed the designated period during the Evaluation Period - the participant has at least 90% non-missing diary days during the period of time - the participant did not report any seizures during the period.

Time frame:
During the Evaluation Period (up to 39 months)
Reported as:
Number · percentage of participants
Percentage of Participants Continuously Seizure-free for Partial Seizure and All Seizure Types During the Evaluation Period for Directly Enrolled Study Participants
percentage of participantsDirect Enrollers BRV
Participants with partial seizure-freedom5.9
Participants with all-type seizure-freedom5.9

Adverse events

Collected over From Baseline until end of the safety follow up (up to 88.5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EP0083 Placebo0/54 (0%)6/54 (11.1%)41/54 (75.9%)
EP0083 BRV All0/112 (0%)23/112 (20.5%)87/112 (77.7%)
N01379 BRV0/7 (0%)5/7 (71.4%)6/7 (85.7%)
Direct Enrollers BRV0/34 (0%)6/34 (17.6%)27/34 (79.4%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventEP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRV
Brain operationSurgical and medical procedures1/540/1122/70/34
Myocardial infarctionCardiac disorders0/540/1121/70/34
Synovial cystMusculoskeletal and connective tissue disorders0/540/1121/70/34
CranioplastySurgical and medical procedures0/540/1121/70/34
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/540/1120/72/34
Sinus node dysfunctionCardiac disorders0/540/1120/71/34
Corona virus infectionInfections and infestations0/540/1120/71/34
PeritonitisInfections and infestations0/540/1120/71/34
Lumbar vertebral fractureInjury, poisoning and procedural complications0/540/1120/71/34
Scapula fractureInjury, poisoning and procedural complications0/540/1120/71/34
Most frequent other events
Showing 10 of 22
Most frequent other events
EventEP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRV
NasopharyngitisInfections and infestations20/5418/1123/79/34
DizzinessNervous system disorders12/5417/1123/75/34
Corona virus infectionInfections and infestations13/5432/1120/711/34
Abdominal pain upperGastrointestinal disorders2/546/1122/72/34
ContusionInjury, poisoning and procedural complications7/5411/1122/74/34
SomnolenceNervous system disorders14/548/1122/76/34
Upper respiratory tract infectionInfections and infestations5/5423/1120/71/34
PyrexiaGeneral disorders9/5421/1121/76/34
HeadacheNervous system disorders10/5421/1120/73/34
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/5411/1121/75/34

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS) which consisted of all participants who took at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)EP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRVTotal
Mean34.5 ± 11.635.8 ± 13.540.7 ± 10.942.2 ± 18.636.7 ± 14.1
Age, Customized
Age, Customized(Participants)EP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRVTotal
12 - <18 yrs24017
18 - <65 yrs52104729192
65 - <85 yrs04037
>=85 yrs00011
Sex: Female, Male
Sex: Female, Male(Participants)EP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRVTotal
Female3253319107
Male2259415100
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRVTotal
Asian54112734207
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EP0083 PlaceboEP0083 BRV AllN01379 BRVDirect Enrollers BRVTotal
Japanese3258734131
Chinese22530075
Other01001
08

Study locations

59 sites
  • Ep0085 905
    Beijing, China
  • Ep0085 901
    Chengdu, China
  • Ep0085 902
    Guangzhou, China
  • Ep0085 909
    Guangzhou, China
  • Ep0085 917
    Guangzhou, China
  • Ep0085 920
    Guangzhou, China
  • Ep0085 924
    Guangzhou, China
  • Ep0085 912
    Hangzhou, China
  • Ep0085 908
    Lanzhou, China
  • Ep0085 921
    Nanchang, China
  • Ep0085 926
    Pingxiang, China
  • Ep0085 910
    Shijiazhuang, China
  • Ep0085 925
    Suzhou, China
  • Ep0085 913
    Wenzhou, China
  • Ep0085 930
    Xinxiang, China
  • Ep0085 916
    Yinchuan, China
  • Ep0085 918
    Zhanjiang, China
  • Ep0085 904
    Zhengzhou, China
  • Ep0085 923
    Zunyi, China
  • Ep0085 148
    Adachi-ku, Japan
  • Ep0085 116
    Asaka, Japan
  • Ep0085 126
    Bunkyō City, Japan
  • Ep0085 127
    Bunkyō City, Japan
  • Ep0085 122
    Hachinohe, Japan
  • Ep0085 111
    Hamamatsu, Japan
  • Ep0085 141
    Higashisonogi-gun Kawatana-cho, Japan
  • Ep0085 110
    Hiroshima, Japan
  • Ep0085 121
    Itami, Japan
  • Ep0085 102
    Kagoshima, Japan
  • Ep0085 142
    Kamakura, Japan
  • Ep0085 140
    Kawasaki, Japan
  • Ep0085 123
    Kodaira, Japan
  • Ep0085 115
    Kokubunji, Japan
  • Ep0085 132
    Kōriyama, Japan
  • Ep0085 112
    Kōshi, Japan
  • Ep0085 128
    Kurume, Japan
  • Ep0085 124
    Kyoto, Japan
  • Ep0085 147
    Kyoto, Japan
  • Ep0085 105
    Nagakute, Japan
  • Ep0085 118
    Nagoya, Japan
  • Ep0085 136
    Nagoya, Japan
  • Ep0085 117
    Nara, Japan
  • Ep0085 129
    Neyagawa, Japan
  • Ep0085 106
    Niigata, Japan
  • Ep0085 850
    Osaka, Japan
  • Ep0085 130
    Ôsaka, Japan
  • Ep0085 131
    Ōtsu, Japan
  • Ep0085 114
    Saitama, Japan
  • Ep0085 101
    Sapporo, Japan
  • Ep0085 103
    Sendai, Japan
  • Ep0085 144
    Shinjuku-ku, Japan
  • Ep0085 104
    Shizuoka, Japan
  • Ep0085 108
    Suita, Japan
  • Ep0085 137
    Suita, Japan
  • Ep0085 138
    Tsukuba, Japan
  • Ep0085 133
    Ushiku, Japan
  • Ep0085 109
    Yamagata, Japan
  • Ep0085 120
    Yokohama, Japan
  • Ep0085 150
    Yokohama, Japan
09

References and documents

Publications

  • Fujimoto A, Qin B, Bourikas D, Dickson N, Moseley B, Sano T, Soma T, Sun W, Watanabe J, Zhou D, Inoue Y. Safety, Tolerability, and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients with Focal-Onset Seizures: Interim Analysis of a Phase 3 Open-Label Extension Trial. Adv Ther. 2025 Sep;42(9):4335-4349. doi: 10.1007/s12325-025-03253-0. Epub 2025 Jun 23. PubMed 40549270 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Dec 2024, 88 months.

Results were first posted in Jul 2025, 7 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 88 months is above that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2017
First posted
Aug 15, 2017
StartActual
Aug 5, 2017
Primary completionActual
Dec 24, 2024
CompletionActual
Dec 24, 2024
Results first posted
Jul 29, 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03250377
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Aug 15, 2017
Start date
Aug 5, 2017
Primary completion
Dec 24, 2024
Completion
Dec 24, 2024
Results posted
Jul 29, 2025
Last update
Jul 29, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion